Daybue (trofinetide) prior authorization for Rett syndrome
Customize your policy alerts
Sign up for all Georgia Department of Community Health policy alerts
Know when Georgia Department of Community Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization criteria and administrative details for coverage of Daybue (trofinetide) for Georgia Medicaid fee-for-service members, including eligibility, prescriber requirements, and authorization length.
No material clinical or coverage changes in this revision.
Coverage Criteria for Daybue (trofinetide)
Initial therapy — Covered when ALL of the following are met
Covered when ALL of the following are met
ALL of the following
- Member eligibility: Member is 2 years of age or older.age >= 2 years
- Diagnosis of classical/typical Rett syndrome confirmed by mutation(s) in the methyl CpG binding protein 2 (MECP2) gene.
- Baseline clinical documentation: Documentation of disease severity by the Rett Syndrome Behavioral Questionnaire (RSBQ) score and Clinical Global Impression–Severity (CGI-S) score.
- Prescriber requirement: Medication prescribed by or in consultation with a neurologist, geneticist, or developmental pediatrician experienced in the treatment of Rett syndrome.
Prescriber specialty required
Exceptions to the conditions of coverage for Daybue (trofinetide) are considered through the prior authorization process. Providers may initiate the prior authorization review by calling OptumRx at 1-866-525-5827.
Daybue is not approvable unless all core criteria are met: the member is aged 2 years or older, has a diagnosis of classical/typical Rett syndrome confirmed by mutation(s) in the MECP2 gene, and baseline severity is documented by the Rett Syndrome Behavioral Questionnaire (RSBQ) and the Clinical Global Impression–Severity (CGI‑S) score. In addition, the medication must be prescribed by or in consultation with a neurologist, geneticist, or developmental pediatrician experienced in treating Rett syndrome. Requests that lack these required confirmations or documentation may be denied.
Coding and Eligibility Basics
| trofinetide | Daybue (trofinetide) — medication name listed on PDL |
Provider Actions and Prior Authorization
Prior authorization required; initial authorization 6–12 months
Prior authorization is required for Daybue (trofinetide). Initial authorizations are issued for a length of 6 to 12 months.
No step therapy required
This policy does not specify any step therapy requirements for Daybue (trofinetide).
Required clinical documentation: MECP2, RSBQ and CGI‑S, prescriber specialty
Include documentation confirming classical/typical Rett syndrome with mutation(s) in the MECP2 gene and baseline severity assessments using the Rett Syndrome Behavioral Questionnaire (RSBQ) score and the Clinical Global Impression–Severity (CGI-S) score. Also document the prescribing clinician specialty or consultation (neurologist, geneticist, or developmental pediatrician).
Initiate PA via OptumRx; exceptions handled through PA
Prior authorization requests may be initiated by calling OptumRx; exceptions to the coverage conditions are considered through the prior authorization process.
- PA initiation phone: OptumRx at 1-866-525-5827
- Exceptions to the conditions of coverage are evaluated via the PA process
Verify eligibility and required documentation to avoid denials
Verify eligibility and required documentation before submission. Requests may be denied if the member is not ≥2 years of age, does not have classical/typical Rett syndrome confirmed by MECP2 mutation, or if RSBQ/CGI‑S scores, prescriber specialty/consultation, or other required documentation are missing.
- Minimum member age for approval: ≥ 2 years
- Diagnosis must be classical/typical Rett syndrome with MECP2 mutation confirmation
- Baseline RSBQ and CGI‑S scores must be documented
- Medication must be prescribed by or in consultation with a neurologist, geneticist, or developmental pediatrician
Definitions and Measurement Tools
Background
Rett syndrome is a neurodevelopmental disorder most often caused by pathogenic variants in the MECP2 gene. Daybue (trofinetide) is indicated for treatment of Rett syndrome and, per this policy, is approvable for members 2 years of age or older with genetically confirmed classical/typical Rett syndrome when baseline severity is documented by the RSBQ and CGI‑S and the drug is prescribed by or in consultation with an appropriate specialist.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.